Abstract: The present invention has its object to provide a transgenic bird producing erythropoietin at high concentration levels as well as a method for constructing the same. The present invention provides a G0 transgenic chimera bird as obtained by incubating a fertilized avian egg, infecting the early embryo formed after egg laying, except for the blastoderm stage immediately following egg laying, with a replication-deficient retroviral vector containing a foreign erythropoietin gene and allowing the embryo to hatch.

Abstract: The present invention provides a G1 transgenic bird or an offspring thereof by: incubating a fertilized avian egg, microinjecting, into the early embryo thereof at a stage except for and after the blastodermic stage just after egg laying, a replication-deficient retroviral vector coding for a useful protein, allowing the egg to hatch out to thereby obtain a G0 transgenic chimeric bird, and mating the G0 transgenic chimeric bird with another G0 transgenic chimeric bird or an offspring thereof or with a wild-type bird.

Abstract: The present invention provides a protein having a ?1,3-galactosyltransferase activity derived from a microorganism; a DNA encoding the protein; a recombinant DNA containing the DNA and a vector; a transformant obtained by introducing the recombinant DNA into a host cell; a method for producing a protein having a ?1,3-galactosyltransferase activity using the transformant; and a method for producing a galactose-containing carbohydrate using the transformant.

Abstract: The present invention provides a lentivirus vector which comprises a coat protein containing VSV-G; a recombinant bird host which is constructed by infecting a bird host with the lentivirus vector; a method of constructing the same; a transgenic chimeric bird which is constructed by infection with the lentivirus vector and offspring thereof. The present invention also provides a method of constructing a G0 transgenic chimeric bird and offspring thereof which comprises infecting fertilized bird egg early embryos with a lentivirus vector comprising a coat protein containing VSV-G, and incubating the embryos; and a G0 transgenic chimeric bird and offspring thereof which is constructed by the method mentioned above. The present invention provides a transgenic bird which is constructed by infecting a bird early embryos with a lentivirus vector comprising a coat protein pseudotyped with VSV-G.

Abstract: The present invention has for its object to provide a G0 transgenic chimera bird which is introduced an antibody gene with a replication-defective retrovirus vector, and produces an antibody by expressing the transgene; a production method of an antibody which comprises recovering the antibody expressed by the produced G0 transgenic chimera bird; and a production method of a G0 transgenic chimera bird which comprises incubating a bird fertile egg, and injecting an embryo after and exclusive of a period immediately after the start of incubation with a retrovirus vector. That is, the present invention relates to a G0 transgenic chimera bird which is introduced an antibody gene with a replication-defective retrovirus vector, and produces an antibody by expressing a transgene.

Abstract: The present invention provides a protein having a ?1,3-galactosyltransferase activity derived from a microorganism; a DNA encoding the protein; a recombinant DNA containing the DNA and a vector; a transformant obtained by introducing the recombinant DNA into a host cell; a method for producing a protein having a ?1,3-galactosyltransferase activity using the transformant; and a method for producing a galactose-containing carbohydrate using the transformant.

Abstract: The present invention provides a protein having a &bgr;1,3-galactosyltransferase activity derived from a microorganism; a DNA encoding the protein; a recombinant DNA containing the DNA and a vector; a transformant obtained by introducing the recombinant DNA into a host cell; a method for producing a protein having a &bgr;1,3-galactosyltransferase activity using the transformant; and a method for producing a galactose-containing carbohydrate using the transformant.

Abstract: The invention has a object to provide a G0 transgenic chimera bird which can efficiently accumulate the useful protein in eggs of a female bird in which the protein is expressed in an oviduct-specific manner and can accumulate even a toxic protein in eggs with no ill effect for birds, and a transgenic bird and a method of producing them. The above object can be attained by providing a G0 transgenic chimera bird and transgenic bird obtained by introducing a replication-defective retrovirus vector coding for a useful protein by an oviduct-specific expression promoter.

Abstract: The present invention provides a protein having a &bgr;1,3-galactosyltransferase activity derived from a microorganism; a DNA encoding the protein; a recombinant DNA containing the DNA and a vector; a transformant obtained by introducing the recombinant DNA into a host cell; a method for producing a protein having a &bgr;1,3-galactosyltransferase activity using the transformant; and a method for producing a galactose-containing carbohydrate using the transformant.

Abstract: The present invention relates to the technology for inhibiting the cancer metastasis, and is aimed at the provision of a pharmaceutical composition for effectively inhibiting the metastasis of the cancer. A cancer metastasis inhibitor according to the present invention is characterized by containing a sugar chain separated from a surface of a Streptococcus agalactiae Ia type or Ib type as a main ingredient. Since the surface sugar chains of the Streptococcus agalactiae Ia type or Ib type have structures similar to surface sugar chains of the cancer cells, the former surface sugar chains adhere to E-selectin appearing in an intravascular endothelial cell, competitively inhibit the adhesion between intravascular endothelial cells and the cancer cells, and effectively prevent of the metastasis of the cancer, when the sugar chains exist in blood of a patient.

Abstract: The present invention relates to an apparatus for performing a fluoroimmunoassay, the apparatus comprising an excitation light source, a fluorescence detector, an optical fiber for an excitation light from the excitation light source to which an antigen or antibody is bound, and a spectroscope, in which the mentioned antigen or antibody is bound to an outgoing end surface of the optical fiber for the excitation light. In the apparatus the spectroscope is constructed so that it introduces the excitation light emitted from the excitation light source to a incident end surface of the optical fiber for the excitation light and introduces a fluorescence emitted from a fluorescence-labeled antibody or antigen which forms an immunological complex with the antigen or antibody to the fluorescence detector. In the apparatus the outgoing end surface of the optical fiber for the excitation light has a transmittance for the excitation light from the excitation light source.

Abstract: The present invention is directed to a method for producing an optical fiber having formyl groups on a core surface. In one embodiment, a plastic optical fiber having formyl groups on a core surface is obtained by immersing the core surface of the plastic optical fiber in a treating solution containing at least a 0.5 to 40 mM alkali metal hydroxide and a compound having formyl groups in water or lower alcohol solvent. In the other embodiment, a plastic optical fiber having formyl groups on a core surface is obtained by introducing a vic-diol group, a primary hydroxyl group or an alkenyl group on the core surface, and then oxidizing it. Turbidity on the core surface of the optical fiber thus obtained is minimized, thereby reducing the transmittance losses of light.

Abstract: A biocatalyst is immobilized with a graft product of a polymer and saponified polyvinyl acetate containing a stilbazolium group as a photo-crosslinking group. The polymer is preferably gelatin, collagen, starch, cellulose, gum arabic, tragacanth gum, carrageenan, mannan, dextrin or alginic acid. The graft product is prepared by bonding the polymer to the polyvinyl acetate, either directly through functional groups of the polymer and polyvinyl acetate or through a crosslinking agent. The polymer provides affinity for the biocatalyst and by grafting the polymer to the saponified polyvinyl acetate, damage to cells upon immobilization is reduced. A liquid composition containing a biocatalyst and the graft product is added to an aqueous solution of an inorganic salt or an organic salt to form a granular gel and the gel is irradiated with actinic rays to cure the gel.

Abstract: A method comprising passing a culture solution including Bacillus subtilis or gene-recombinated Bacillus thereof through a pipe-like ceramic filter at a flow rate of 2 m/sec or less, the ceramic filter having a filter layer at an inner cylindrical surface thereof, the filter layer being made of spherical particles, and a surface roughness (Rmax) of the inner surface of the ceramic filter being 10 microns or less.